DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2

References

• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–598. doi:10.1038/nrc218917646864
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992. doi:10.1038/leu.2013.29324177258
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. doi:10.1038/leu.2013.31324157580
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Gertz MA, Dispenzieri A, et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016;30(3):633–639. doi:10.1038/leu.2015.28726487275
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:10.1016/j.cell.2006.01.01616469695
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev. 2009;35(2):148–159. doi:10.1016/j.ctrv.2008.09.00619013721
   PubMed Web of Science ®Google Scholar
• Calimeri T, Ferreri A. m-TOR inhibitors and their potential role in haematological malignancies. Br J Haematol. 2017;177(5):684–702. doi:10.1111/bjh.1452928146265
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293. doi:10.1016/j.cell.2012.03.01722500797
   PubMed Web of Science ®Google Scholar
• Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280(49):40406–40416. doi:10.1074/jbc.M50836120016221682
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–1101. doi:10.1126/science.110614815718470
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82(12):3712–3720. 8260708
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10–24. doi:10.1038/leu.2008.25918843284
   PubMed Web of Science ®Google Scholar
• Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011;118(26):6860–6870. doi:10.1182/blood-2011-03-34239422045983
   PubMed Web of Science ®Google Scholar
• Suganya N, Bhakkiyalakshmi E, Subin TS, et al. Proteomic identification of pterostilbene-mediated anticancer activities in HepG2 cells. Chem Res Toxicol. 2014;27(7):1243–1252. doi:10.1021/tx500139224936659
   PubMed Web of Science ®Google Scholar
• Roslie H, Chan KM, Rajab NF, et al. 3,5-dibenzyloxy-4‘-hydroxystilbene induces early caspase-9 activation during apoptosis in human K562 chronic myelogenous leukemia cells. J Toxicol Sci. 2012;37(1):13–21. 22293408
   PubMed Web of Science ®Google Scholar
• Liu X, Xu Z, Hou C, et al. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol. 2016;103:118–128. doi:10.1016/j.bcp.2016.01.00326774458
   PubMed Web of Science ®Google Scholar
• Ashton JC. Drug combination studies and their synergy quantification using the Chou-Talalay method–letter. Cancer Res. 2015;75(11):2400. doi:10.1158/0008-5472.CAN-14-356925977339
   PubMed Web of Science ®Google Scholar
• Nikhil K, Sharan S, Roy P. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFkappaB and MAPK signaling in RAW264.7 cells. Pharmacol Rep. 2015;67(6):1264–1272. doi:10.1016/j.pharep.2015.05.00926481551
   PubMed Web of Science ®Google Scholar
• Kong Y, Chen G, Xu Z, et al. Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells. Sci Rep. 2016;6:37417. doi:10.1038/srep3741727869173
   PubMed Web of Science ®Google Scholar
• Xie B, Xu Z, Hu L, et al. Pterostilbene inhibits human multiple myeloma cells via ERK1/2 and JNK pathway in vitro and in vivo. Int J Mol Sci. 2016;17:11. doi:10.3390/ijms17111927
   Web of Science ®Google Scholar
• Sankhala K, Giles FJ. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies. Expert Rev Hematol. 2009;2(4):399–414. doi:10.1586/ehm.09.3121082945
   PubMed Web of Science ®Google Scholar
• Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104(13):4181–4187. doi:10.1182/blood-2004-03-115315304393
   PubMed Web of Science ®Google Scholar
• O‘Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–1508. doi:10.1158/0008-5472.CAN-05-292516452206
   PubMed Web of Science ®Google Scholar
• Abramson HN. Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget. 2016;7(49):81926–81968. doi:10.18632/oncotarget.1074527655636
   PubMedGoogle Scholar
• Rajan AM, Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J. 2016;6(7):e451. doi:10.1038/bcj.2016.5327471867
   PubMed Web of Science ®Google Scholar
• Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52. doi:10.1186/s13045-016-0282-127363832
   PubMed Web of Science ®Google Scholar
• Bendell JC, Kelley RK, Shih KC, et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer Am Cancer Soc. 2015;121(19):3481–3490.
   Google Scholar
• Chen X, Diaz-Rodriguez E, Ocio EM, et al. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Mol Cancer Ther. 2014;13(2):504–516. doi:10.1158/1535-7163.MCT-13-002224431075
   PubMed Web of Science ®Google Scholar
• Cirstea D, Santo L, Hideshima T, et al. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014;13(11):2489–2500. doi:10.1158/1535-7163.MCT-14-014725172964
   PubMed Web of Science ®Google Scholar
• Lee KB, Byun HJ, Park SH, Park CY, Lee SH, Rho SB. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 2012;315(1):86–95. doi:10.1016/j.canlet.2011.10.01622078465
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2(12):927–937. doi:10.1038/nrc95212459731
   PubMed Web of Science ®Google Scholar
• Gunther A, Baumann P, Burger R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100(4):541–547. doi:10.3324/haematol.2014.11626925682600
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol. 2011;29(25):3427–3434. doi:10.1200/JCO.2010.32.496221825263
   PubMed Web of Science ®Google Scholar
• Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12(17):5165–5173. doi:10.1158/1078-0432.CCR-06-076416951235
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011;12(3):263–272. doi:10.1016/S1470-2045(11)70028-621345726
   PubMed Web of Science ®Google Scholar
• Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, Cugno M. Current and emerging treatment options for patients with relapsed myeloma. Clin Med Insights Oncol. 2013;7:209–219. doi:10.4137/CMO.S801424179412
   PubMedGoogle Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734. doi:10.1002/ajh.2440227291302
   PubMed Web of Science ®Google Scholar